Increase in both CEA and CA19-9 in sera is an independent prognostic indicator in colorectal carcinoma

Journal of Surgical Oncology

Volumn 94, Issue 2, 2006, Pages 132-137

  Nozoe, Tadahiro ^a   Rikimaru, Tatsuya ^a   Mori, Emiko ^a   Okuyama, Toshiro ^a   Takahashi, Ikuo ^a  

^a FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

Author keywords

Carbohydrate antigen (CA19 9); Carcinoembryonic antigen (CEA); Colorectal carcinoma; Prognostic indicator

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL FEATURE; COLORECTAL CARCINOMA; COLORECTAL SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; BLOOD; COLON TUMOR; IMMUNOLOGY; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; RECTUM TUMOR; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECTAL NEOPLASMS; SIGMOID NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33747113107     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20577     Document Type: Article

References (12)

1. Hammarstrom S: The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81.
2. McLeod HL, Murray GI: Tumour markers of prognosis in colorectal cancer. Br J Cancer 1999;79:191-203.
3. Chapman MA, Buckley D, Henson DB, et al.: Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. Br J Cancer 1998;78:1346-1349.
4. Duffy MJ: Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clin Chem 2001;47:624-630.
5. Nakagoe T, Sawai T, Tsuji T, et al.: Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients. Hepatogastroenterology 2003;50:696-699.
6. Japanese Research Society for Cancer of the Colon and Rectum: General rules for clinical and pathologic studies on cancer of the colon, rectum and anus. Jpn J Surg 1983;13:557-573.
7. Sobin LH, Wittekind C: International union against cancer. TNM classification of malignant tumours, fifth edition. New York: Wiley-Liss, 1997: pp 54-58.
8. Dukes CE, Bussey HJR: The spread of rectal cancer and its effect on prognosis. Br J Cancer 1958;12:309-320.
9. Duffy MJ, van Dalen A, Haglund C, et al.: Clinical utility of biochemical markers in colorectal cancer: European group on tumour markers (EGTM) guidelines. Eur J Cancer 2003;39:718-727.
10. Louhimo J, Carpelan-Holmstrom M, Alfthan H, et al.: Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 2002;101:545-548.
11. Morita S, Nomura T, Fukushima Y, et al.: Does serum CA19-9 play a practical role in the management of patients with colorectal cancer? Dis Colon Rectum 2004;47:227-232.
12. Reiter W, Stieber P, Reuter C, et al.: Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma. Anticancer Res 1997;17:2935-2938.